ABOUT US
We are targeting HSV Unmet Medical Needs which affects over 4.5 billion of patients worldwide
ABOUT US
We are targeting HSV Unmet Medical Needs which affects over 4.5 billion of patients worldwide
ABOUT US
We are targeting HSV Unmet Medical Needs which affects over 4.5 billion of patients worldwide
OVERVIEW
The company was founded to harness the power of Reactive Oxygen Species (ROS) in discovering and developing effective and safe treatments for Herpes.
OXYMO Technologies, Inc. is a Canadian biotech company focusing on a groundbreaking antiviral therapeutic approach that directly targets HSV and Heparan Sulfate receptors. Discovery research and preclinical development were performed by leading European CROs and renowned French Universities in collaboration with the Institut Pasteur Paris. OXYMO Technologies has successfully completed the preclinical development of its first clinical drug candidate Oximo, and submitted a pre-IND application to the US FDA for the treatment of Recurrent Herpes Labialis (RHL). Oximo is scheduled to enter Phase I clinical trial in 2027 and Phase II trial in 2028, in collaboration with the University of Washington in Seattle, USA, to demonstrate proof of concept (POC) in RHL patients.
1. World Health Organization 2022
491 million
3.7 billion
people under age 50 (67%) are HSV-1 infected 1
OVERVIEW
The company was founded to harness the power of Reactive Oxygen Species (ROS) in discovering and developing effective and safe treatments for Herpes.
OXYMO Technologies, Inc. is a Canadian biotech company focusing on a groundbreaking antiviral therapeutic approach that directly targets HSV and Heparan Sulfate receptors. Discovery research and preclinical development were performed by leading European CROs and renowned French Universities in collaboration with the Institut Pasteur Paris. OXYMO Technologies has successfully completed the preclinical development of its first clinical drug candidate Oximo, and submitted a pre-IND application to the US FDA for the treatment of Recurrent Herpes Labialis (RHL). Oximo is scheduled to enter Phase I clinical trial in 2027 and Phase II trial in 2028, in collaboration with the University of Washington in Seattle, USA, to demonstrate proof of concept (POC) in RHL patients.
1. World Health Organization 2022
491 million
3.7 billion
people under age 50 (67%) are HSV-1 infected 1
OVERVIEW
The company was founded to harness the power of Reactive Oxygen Species (ROS) in discovering and developing effective and safe treatments for Herpes.
OXYMO Technologies, Inc. is a Canadian biotech company focusing on a groundbreaking antiviral therapeutic approach that directly targets HSV and Heparan Sulfate receptors. Discovery research and preclinical development were performed by leading European CROs and renowned French Universities in collaboration with the Institut Pasteur Paris. OXYMO Technologies has successfully completed the preclinical development of its first clinical drug candidate Oximo, and submitted a pre-IND application to the US FDA for the treatment of Recurrent Herpes Labialis (RHL). Oximo is scheduled to enter Phase I clinical trial in 2027 and Phase II trial in 2028, in collaboration with the University of Washington in Seattle, USA, to demonstrate proof of concept (POC) in RHL patients.
1. World Health Organization 2022
3.7 billion
people under age 50 (67%) are HSV-1 infected 1
491 million
people aged 15-49 (13%) is infected with HSV-21
Working in collaboration with leading institutes
Working in collaboration with leading institutes
Working in collaboration with leading institutes
OUR TIMELINE
Oximo Development Timelines
First topical drug candidate designed to intervene at the early stage of recurrent herpas episodes, with the objective of preventing lesion development and accelerating return to normal skin.
2015
Creation of OXYMO Technologies Inc.
Foundational IP and platform established
2019
Strategic Investor Entry & Team Build-Out
Private investor joins
2023
Pre-IND completion
Regulatory positioning & development plan defined
2027
CTA/IND Approval - Phase I (Canada)
Phase I data expected in 4Q 2027
2028-2029
Phase II Proof of Concept (Canada & USA)
Multicenter Phase II with the University of Washington Virology Research Clinic, Seattle, USA - POC in RHL patients - Phase II data expected in 2Q 2029
2030-2031
Phase III Pivotal Trial for Registration (if needed)
Phase III data expected in 4Q 2031
2031-2032
Strategic Partnership/Global Commercialization
Partner for late stage execution and launch
OUR TIMELINE
Oximo Development Timelines
First topical drug candidate designed to intervene at the early stage of recurrent herpas episodes, with the objective of preventing lesion development and accelerating return to normal skin.
2015
Creation of OXYMO Technologies Inc.
Foundational IP and platform established
2019
Strategic Investor Entry & Team Build-Out
Private investor joins
2023
Pre-IND completion
Regulatory positioning & development plan defined
2027
CTA/IND Approval - Phase I (Canada)
Phase I data expected in 4Q 2027
2028-2029
Phase II Proof of Concept (Canada & USA)
Multicenter Phase II with the University of Washington Virology Research Clinic, Seattle, USA - POC in RHL patients - Phase II data expected in 2Q 2029
2030-2031
Phase III Pivotal Trial for Registration (if needed)
Phase III data expected in 4Q 2031
2031-2032
Strategic Partnership/Global Commercialization
Partner for late stage execution and launch
OUR TIMELINE
Oximo Development Timelines
First topical drug candidate designed to intervene at the early stage of recurrent herpas episodes, with the objective of preventing lesion development and accelerating return to normal skin.
2015
Creation of OXYMO Technologies Inc.
Foundational IP and platform established
2019
Strategic Investor Entry & Team Build-Out
Private investor joins
2023
Pre-IND completion
Regulatory positioning & development plan defined
2027
CTA/IND Approval - Phase I (Canada)
Phase I data expected in 4Q 2027
2028-2029
Phase II Proof of Concept (Canada & USA)
Multicenter Phase II with the University of Washington Virology Research Clinic, Seattle, USA - POC in RHL patients - Phase II data expected in 2Q 2029
2030-2031
Phase III Pivotal Trial for Registration (if needed)
Phase III data expected in 4Q 2031
2031-2032
Strategic Partnership/Global Commercialization
Partner for late stage execution and launch
OUR TEAM
OXYMO Technologies team members are based in Canada, USA & France
Leadership Team
Felix Furst
President
Olivier Chretien
CEO and Co-Founder
Françoise Marechal
Director and Co-Founder
R&D Team
Professor Remi Wilmotte
Chemist and Co-Founder
Michel Hubert
Pharmacist Corporate Development
Pierre Attali, MD
Chief Medical Officer Former CMO Onxeo SA - HSV Drug Development
Catherine Bernard, PhD
US Agent and Regulatory Affairs
Caroline Diveu Sader, PhD
Project Leader
Scientific and Clinical Advisory Board
Phil Krause, MD
Ex Deputy Director, FDA/CBER/OVRR
Ed Mocarski, PhD
Emeritus Professor at Stanford and Emory Universities
